Obicetrapib Approved in Europe: LDL, Lp(a) and What the Evidence Shows

Summary

• On 21 September 2026 the European Commission authorized Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg + ezetimibe 10 mg), the first approval of obicetrapib anywhere in the world.
• In Phase 3 trials, obicetrapib lowered LDL-C by roughly 30–40% versus placebo on top of existing therapy; the combination with ezetimibe lowered it by about 50%.
• In a pooled analysis, it also lowered Lp(a) by about 37% overall and about 43% in people with baseline Lp(a) of 50 to under 150 nmol/L.
• Whether it reduces heart attacks and strokes is not yet proven. The PREVAIL outcomes trial has an interim analysis planned for late 2026, with results expected in early 2027.
• It is not approved by the FDA in the United States as of this writing.

1. What was approved

The European Commission granted marketing authorization for two once-daily tablets: Ubeslo (obicetrapib 10 mg) and Evlarco, a fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg. Both are approved for adults with primary hypercholesterolemia (familial or non-familial) or mixed dyslipidemia, as an addition to diet.

According to the European Medicines Agency, obicetrapib is intended for people who cannot reach their LDL-C goal on the maximum tolerated dose of a statin (used together with the statin), or alone or with other cholesterol-lowering medicines in people who cannot take a statin.

Availability: authorization is not the same as availability. The companies have said launches may begin in Germany and the UK in late 2026; access and reimbursement will differ from country to country. In the United States, obicetrapib is not FDA-approved, and the company has said US filing plans are being discussed with the FDA in light of the PREVAIL interim analysis.

2. What is a CETP inhibitor?

Cholesteryl ester transfer protein (CETP) moves cholesterol between lipoprotein particles in the blood. Blocking it raises HDL cholesterol and, with potent inhibitors such as obicetrapib, substantially lowers LDL cholesterol and apolipoprotein B. This is a different pathway from statins (which reduce cholesterol production in the liver) and ezetimibe (which reduces cholesterol absorption in the gut).

The class has a difficult history. Torcetrapib raised blood pressure and increased deaths in its outcomes trial; dalcetrapib and evacetrapib showed no significant reduction in cardiovascular events in their outcomes trials; anacetrapib produced a modest reduction in major coronary events in the large REVEAL trial but was never brought to market. Obicetrapib was designed to lower LDL-C much more strongly than its predecessors, and that is the hypothesis PREVAIL is testing.

3. How much does it lower LDL?

The approval rests mainly on three Phase 3 trials in people already taking cholesterol-lowering therapy:

Across the program the companies report LDL-C reductions of up to about 40% with obicetrapib alone and about 50% with the ezetimibe combination, compared with placebo. These are average trial results; individual responses vary.

4. What about Lp(a)?

A pooled analysis published in the European Heart Journal in 2026 looked at Lp(a) after 12 weeks. Overall, obicetrapib lowered Lp(a) by about 37% compared with placebo (the median baseline was low, about 43 nmol/L). In people with baseline Lp(a) of 50 to under 150 nmol/L, the placebo-adjusted reduction was about 43%. People starting at 150 nmol/L or higher had a smaller percentage reduction, although the absolute drop in nmol/L was broadly similar.

Two cautions. First, these reductions are much smaller than those of the Lp(a)-specific drugs in development, which lower Lp(a) by roughly 80% or more (see Lp(a)-lowering drugs in 2026). Second, it has not been shown that the Lp(a) reduction from obicetrapib, on its own, prevents cardiovascular events. This matters more since September 2026, when the first outcomes trial of an Lp(a)-specific drug, Lp(a)HORIZON with pelacarsen, did not meet its primary endpoint despite lowering Lp(a).

5. Does it prevent heart attacks?

Not yet proven. BROADWAY was designed to measure LDL-C, not events. In an exploratory safety analysis, major adverse cardiovascular events were 21% lower with obicetrapib, but the confidence interval was wide and included no effect (hazard ratio 0.79, 95% CI 0.54–1.15), so this cannot be treated as evidence of benefit.

The answer will come from PREVAIL, a cardiovascular outcomes trial in more than 9,000 people with established atherosclerotic disease whose LDL-C is not controlled on maximally tolerated therapy. The company plans an interim analysis in the fourth quarter of 2026, with the result expected in the first quarter of 2027. If the trial is not stopped early, completion is expected by the end of 2027.

Given the history of the CETP class, this is the result that matters most. LDL-C lowering by other drug classes has reliably translated into fewer events, but that has to be demonstrated for each new mechanism.

6. Side effects and safety

In the Phase 3 trials, tolerability was broadly similar to placebo. The European Medicines Agency lists the most common side effects as high blood pressure, dizziness, headache, diarrhea and abdominal pain. Because earlier CETP inhibitors had safety problems, longer-term data from PREVAIL will also be important for safety, not only for benefit.

7. What it means for you

If your LDL-C is above the goal your clinician has set despite a statin, there are already several proven add-on options, including ezetimibe, PCSK9 inhibitors and bempedoic acid. In Europe, obicetrapib may become another oral option for people who need more LDL lowering or cannot take a statin. In the United States it is not available.

Do not stop or change a current cholesterol medicine while waiting for a newer one. Questions worth asking your clinician:

• Am I at my LDL-C goal, and what is that goal for my risk?
• If not, which add-on option fits me best today, and why?
• Has my Lp(a) been measured, and does it change how low my LDL-C should go?
• Would a new medicine without outcomes data yet be appropriate for me, or should we prefer treatments proven to reduce events?

Related guides: Statins · Lipoprotein(a) guide · LDL-C and ApoB targets

Sources

1. NewAmsterdam Pharma and Menarini Group. European Commission approval of Ubeslo and Evlarco. Press release, 21 September 2026.
2. European Medicines Agency. Ubeslo (obicetrapib): summary of opinion, CHMP, 23 July 2026.
3. Nicholls SJ, Nelson AJ, Ray KK, et al. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. 2026. doi:10.1093/eurheartj/ehag399
4. BROADWAY: obicetrapib in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia. N Engl J Med. 2025.
5. TANDEM: fixed-dose combination of obicetrapib and ezetimibe. Lancet. 2025.
6. NewAmsterdam Pharma. Quarterly reports and corporate updates (SEC filings), 2026: PREVAIL interim analysis timing.
7. HPS3/TIMI55–REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.